Theriva Biologics, Inc. (TOVX) stock
TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.14+0.00 (0.00%)
Close on Nov 17, 2026Market cap $6.42MP/E –Yield –
Theriva Biologics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Theriva Biologics's ebitda for the twelve months ending Jun 30, 2026 was -$11.82M. For fiscal 2025 it was -$23.94M. The highest annual figure on record is -$9.96M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.94M | – |
| FY2024 | Dec 31, 2024 | -$26.21M | – |
| FY2023 | Dec 31, 2023 | -$21.30M | – |
| FY2022 | Dec 31, 2022 | -$21.50M | – |
| FY2021 | Dec 31, 2021 | -$14.19M | – |
| FY2020 | Dec 31, 2020 | -$9.96M | – |
| FY2019 | Dec 31, 2019 | -$15.42M | – |
| FY2018 | Dec 31, 2018 | -$17.30M | – |
| FY2017 | Dec 31, 2017 | -$26.01M | – |
| FY2016 | Dec 31, 2016 | -$39.10M | – |
| FY2015 | Dec 31, 2015 | -$40.91M | – |
| FY2014 | Dec 31, 2014 | -$20.48M | – |
| FY2013 | Dec 31, 2013 | -$12.30M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.10M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.41M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.19M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.29M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.23M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.25M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.26M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.50M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.97M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.15M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.18M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.19M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.25M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.93M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.92M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.71M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.79M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.42M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.09M | – |
| Q4 FY2016 | Dec 31, 2016 | -$10.16M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.10M | – |
See a number that looks wrong?